<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02110654</url>
  </required_header>
  <id_info>
    <org_study_id>20140329</org_study_id>
    <nct_id>NCT02110654</nct_id>
  </id_info>
  <brief_title>Comparison of Daily Mometasone Furoate Nasal Spray Alone Versus a Combination With Montelukast for Treatment of Chronic Rhinosinusitis With Asthma After Functional Endoscopic Sinus Surgery</brief_title>
  <official_title>Comparison of Daily Mometasone Furoate Nasal Spray Alone Versus a Combination With Montelukast for Treatment of Chronic Rhinosinusitis With Asthma After Functional Endoscopic Sinus Surgery: a 9-month Randomized, Open-label, Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>First Affiliated Hospital, Sun Yat-Sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. objectives. To compare the efficacy and the safety of mometasone furoate nasal spray&#xD;
           (MFNS; Nasonex 200μg, daily) alone versus a combination with montelukast (singulair&#xD;
           10mg, daily) in chronic rhinosinusitis (CRS) with asthma after functional endoscopic&#xD;
           sinus surgery (FESS) for improvement the clinical control of CRS&#xD;
&#xD;
        2. the clinical hypotheses. The investigators hypothesize that postoperative combined&#xD;
           montelukast and MFNS can better improve clinical control of CRS concomitant with asthma&#xD;
           after FESS compared with MFNS alone.&#xD;
&#xD;
        3. study design This study is a 9-month randomized, open-label, controlled interventional&#xD;
           study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Surgery plan&#xD;
&#xD;
             -  Pre-operation: Patients enrolled in the study will complete assessment and specimen&#xD;
                collection on the first day, then followed by 1 week drug therapy with prednisone&#xD;
                (30 mg once daily) and MFNS(200ug, once daily).&#xD;
&#xD;
             -  FESS: For patients with no surgical contraindications, FESS will be performed.&#xD;
                Bilateral nasal cavities will be filled with swelling sponges postoperatively. The&#xD;
                stuffing will be removed on postoperative day 2. The patients will be discharged on&#xD;
                day 3 after surgery.&#xD;
&#xD;
             -  Other treatment: All patients will receive nasal irrigation (normal saline 500 mg&#xD;
                twice daily) from postoperative day 3 until day 30. Asthma will be treated as the&#xD;
                guidance of professors from the Department of Respiratory Medicine in the&#xD;
                investigators hospital.&#xD;
&#xD;
        2. Drug treatment phase Three days after the surgery (FESS) described above, all patients&#xD;
           will be assigned to the following two groups (30 patients each group) using random&#xD;
           numbers generated by statistical software.&#xD;
&#xD;
             -  Experimental group: Montelukast (10mg, once daily) and MFNS (200μg, once daily) for&#xD;
                6 months&#xD;
&#xD;
             -  Control group: MFNS (200μg, once daily) for 6 months&#xD;
&#xD;
        3. Follow up After the 6-month drug treatment phase, there are still a 3-month follow-up.&#xD;
           Totally, there are 5 visits after FESS surgery.&#xD;
&#xD;
             -  Visit 1: baseline&#xD;
&#xD;
             -  Visit 2： Day 31 post-FESS&#xD;
&#xD;
             -  Visit 3: Day 61 post-FESS&#xD;
&#xD;
             -  Visit 4: Day 91 post-FESS&#xD;
&#xD;
             -  Visit 5: Day 181 post-FESS&#xD;
&#xD;
             -  Visit 6: Day 271 post-FESS&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">November 1, 2020</completion_date>
  <primary_completion_date type="Actual">November 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>There are two study groups listed as below.&#xD;
Montelukast 10mg once daily + Mometasone furoate nasal spray 100 µg/per nostril once daily for 6 months.&#xD;
Mometasone furoate nasal spray 100 µg/per nostril once daily for 6 months.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with Decrease in Nasal symptome Visual Analogue Scale (VAS)</measure>
    <time_frame>9 months</time_frame>
    <description>nasal symptoms include general symptom, congestion, rhinorrhea, olfactory loss and headache.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Decrease in nasal endoscopy score (Lund-Kennedy score)</measure>
    <time_frame>9 months</time_frame>
    <description>Visit 1: baseline Visit 2：Day 31 post-FESS Visit 3: Day 61 post-FESS Visit 4: Day 91 post-FESS Visit 5: Day 181 post-FESS Visit 6: Day 271 post-FESS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Decrease in sinus CT score (Lund-Mackay, scoring system)</measure>
    <time_frame>6 months</time_frame>
    <description>baseline, 6 months post-FESS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Increase in Asthma Control test (ACT)</measure>
    <time_frame>9 months</time_frame>
    <description>Visit 1: baseline Visit 2：Day 31 post-FESS Visit 3: Day 61 post-FESS Visit 4: Day 91 post-FESS Visit 5: Day 181 post-FESS Visit 6: Day 271 post-FESS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Serious and Non-Serious Adverse Events</measure>
    <time_frame>9 months</time_frame>
    <description>Visit 1: baseline Visit 2：Day 31 post-FESS Visit 3: Day 61 post-FESS Visit 4: Day 91 post-FESS Visit 5: Day 181 post-FESS Visit 6: Day 271 post-FESS</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Sinusitis</condition>
  <condition>Nasal Polyps</condition>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>mometasone furoate nasal spray</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>mometasone furoate nasal spray,200ug qd, 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mometasone furoate nasal spray combined with montelukast</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>montelukast tablet,10mg,qd + mometasone furoate nasal spray, 200ug qd,6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Montelukast</intervention_name>
    <arm_group_label>mometasone furoate nasal spray</arm_group_label>
    <arm_group_label>mometasone furoate nasal spray combined with montelukast</arm_group_label>
    <other_name>singulair</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mometasone furoate nasal spray</intervention_name>
    <arm_group_label>mometasone furoate nasal spray combined with montelukast</arm_group_label>
    <other_name>nasonex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of chronic rhinosinusitis according to European position paper of&#xD;
             rhinosinusitis and nasal polyps 2007&#xD;
&#xD;
          2. Diagnosis of asthma based on Global initiative for asthma 2012&#xD;
&#xD;
          3. All patients should provide informed consent prior to the study and agree to follow-up&#xD;
             appointments.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Immunodeficiency diseases, history of head and/or facial trauma, cancer or organ&#xD;
             transplant recipients.&#xD;
&#xD;
          2. Pregnancy or lactation.&#xD;
&#xD;
          3. Uncontrolled bronchial asthma.&#xD;
&#xD;
          4. Acute respiratory tract infection within one month before the study.&#xD;
&#xD;
          5. Use of leukotriene receptor antagonist within 3 months before the enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>jianbo shi, doctor</last_name>
    <role>Study Director</role>
    <affiliation>Ent department, the first affiliated hospital, Sun Yat-sen University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>the first affiliated hospital, Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>March 31, 2014</study_first_submitted>
  <study_first_submitted_qc>April 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2014</study_first_posted>
  <last_update_submitted>November 19, 2020</last_update_submitted>
  <last_update_submitted_qc>November 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>First Affiliated Hospital, Sun Yat-Sen University</investigator_affiliation>
    <investigator_full_name>Jianbo Shi</investigator_full_name>
    <investigator_title>Deputy director of ENT department</investigator_title>
  </responsible_party>
  <keyword>chronic rhinosinusitis</keyword>
  <keyword>asthma</keyword>
  <keyword>montelukast</keyword>
  <keyword>surgery</keyword>
  <keyword>treatment outcomes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sinusitis</mesh_term>
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Nasal Polyps</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mometasone Furoate</mesh_term>
    <mesh_term>Montelukast</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

